**Background of LGALS2 Antibody**
The LGALS2 antibody targets the protein galectin-2. encoded by the *LGALS2* gene, a member of the galectin family known for binding β-galactoside sugars via conserved carbohydrate recognition domains. Galectin-2 is a small, homodimeric lectin expressed in various tissues, including the gastrointestinal tract, immune cells, and vascular endothelium. It plays roles in inflammation, apoptosis, and immune regulation by interacting with ligands such as lymphotoxin-α, influencing pathways like NF-κB signaling.
Research highlights LGALS2's association with cardiovascular diseases, particularly myocardial infarction, where specific polymorphisms may modulate disease risk. It is also implicated in autoimmune disorders and cancer progression, potentially affecting tumor immunity and metastasis.
LGALS2 antibodies are essential tools for detecting galectin-2 expression and localization in experimental models, using techniques like Western blotting, immunohistochemistry, and flow cytometry. These antibodies aid in studying galectin-2's functional mechanisms, its interaction with cellular components, and its diagnostic or therapeutic potential. Commercial LGALS2 antibodies are typically validated for specificity and cross-reactivity across species (e.g., human, mouse), supporting translational research in disease biomarkers and molecular pathways.